This study is testing whether adding a new immunotherapy drug called ONC-392 to an existing prostate cancer radiation treatment (Pluvicto) is safe and more effective. It is for men whose advanced prostate cancer has worsened despite prior hormone-blocking drugs and chemotherapy. …
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC